French biopharmaceutical company Genfit said on Monday it is to launch a phase 3 study of its treatment for liver disease NASH by year-end as part of an accelerated approval procedure which could allow it to be brought to market in 2019. Genfit shares rose 5 pct to 42.71 euros on the news. There is currently no cure for Non-alcoholic Steatohepatitis (NASH), a degenerative liver disease caused by an excessively rich diet.